February 23, 2026

Sleep Disruption and Osteoarthritis Risk

Investigators find that short sleep, insomnia, and night shift work are associated with increased risk of knee and hip osteoarthritis and joint replacement.

Conexiant

February 19, 2026

Quality of Life in Cardiac Arrest Recovery

Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 17, 2026

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Conexiant

February 17, 2026

CKD Markers Linked to Cognitive Risk

In adults with chronic kidney disease, higher proteinuria and lower estimated glomerular filtration rate are associated with increased risk of incident cognitive impairment.

Conexiant

February 13, 2026

Chronic Cough Despite Normal Workup

Researchers describe diagnostic evaluation and management considerations when standard testing fails to identify the cause of persistent cough.

Conexiant

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

February 12, 2026

Insomnia Outcomes May Vary by Measurement Method 

Smartphone-based symptom tracking highlights gaps in how insomnia treatments are evaluated.

Conexiant

February 12, 2026

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

Conexiant